| Gene symbol | CSF2 | Synonyms | CSF, GMCSF | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q31.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | colony stimulating factor 2 | ||||
| GTO ID | GTC1677 |
| Trial ID | NCT02978625 |
| Disease | Non-Melanoma Skin Cancer |
| Altered gene | GMCSF |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | Talimogene Laherparepvec|Imlygic|T-VEC|JS1 34.5-hGMCSF 47- pA- |
| Co-treatment | Nivolumab |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors |
| Year | 2016 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | NCI-2016-01804|NCI-2016-01804|CINJ #091701|10057|10057|UM1CA186709|UM1CA186716 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||